Psychiatry
Page 1 • 2 itemsGlobal psychiatry market intelligence for pharma BD, investors & analysts. Track drug development, regulatory updates & competitive landscapes.
CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis
New network meta-analysis shows CAPLYTA demonstrated superior efficacy across four key measures compared to other FDA-approved adjunctive MDD therapies.
FDA Approves Johnson & Johnson's CAPLYTA (Lumateperone) sNDA for Schizophrenia Relapse Prevention
FDA approves CAPLYTA supplemental application showing 63% relapse risk reduction in schizophrenia patients with 84% remaining relapse-free over six months.